Media Pack
News

Current Edition

Volume 6 Issue 3

Upcoming Events

Advertisement

 
 
news

FDA clears Gilead to restart some studies of top cancer drug

Dive Brief: The Food and Drug Administration has cleared Gilead to restart some trials testing an experimental cancer drug the company acquired in a roughly $5 bil...
14 April 2022 news cancer | Drug
Continue Reading →
news

Pressure rises as Gilead awaits important study results for top cancer drug

Gilead lost several billion dollars in market value Wednesday after unnerving investors with updates about a key clinical trial of its most closely watched breast can...
10 February 2022 news cancer | clinical
Continue Reading →
news

Pressure rises as Gilead awaits important study results for top cancer drug

Gilead lost several billion dollars in market value Wednesday after unnerving investors with updates about a key clinical trial of its most closely watched breast can...
6 February 2022 news cancer | Drug
Continue Reading →
news

Gilead, following Merck, hits its own safety setback in HIV

The clinical hold comes at an inopportune time for Gilead. Last month, the company's longtime rival Merck & Co. disclosed worrisome findings from a study testing...
7 January 2022 news Gilead | HIV
Continue Reading →
news

Two cancer cell therapy studies succeeded. Why did a third fail?

In two major clinical trials, researchers found cell therapy dramatically outperformed the standard of care used for the past few decades to counter a common type of ...
15 December 2021 news Breyanzi | Bristol Myers Squibb
Continue Reading →
news

Galapagos CEO to retire, though successor yet to be announced

Galapagos looked to be in a strong position at the start of 2020. It had recently closed a major research deal with Gilead that not only provided substantial amounts ...
3 September 2021 news drug development | FDA
Continue Reading →
news

Gilead’s Kite bets on early-stage biotech to advance allogeneic cell therapies

The deal with Appia is yet another step in Gilead’s efforts to become an oncology powerhouse — a strategy the company has made clear through numerous acquisitions and...
13 August 2021 news allogeneic cell therapies | Biotech
Continue Reading →
 
 
 
 
 
IBI-white.png

International Biopharmaceutical Industry

IBI – International Biopharmaceutical Industry was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally.

Facebook Linkedin
Bio Pharmaceutical Media © 2023, All Rights Reserved – Powered by Teksyte